



Certificate of Mailing [37 CFR 1.8(a)]

I hereby certify that this paper and the documents referred to as attached therein are being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Denise Ortega

Name

March 30, 2004

Date

Denise Ortega

Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Jan Zavada et al.

Serial No.: 10/795,933

Group Art Unit:

Filed : March 8, 2004

Examiner:

For : MN Gene and Protein

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR SECTIONS 1.56, 1.97 AND 1.98

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The accompanying PTO Form 1449 is submitted pursuant to 37 CFR Sections 1.56, 1.97 and 1.98, directing Applicants to submit literature and information that may be considered material to the examination of the claims of an application. Applicants respectfully submit that this Information Disclosure Statement (IDS) should be considered in accordance with 37 CFR Section 1.97(b)(1), as it is being submitted within three months of the filing date of the subject application, and that no fee is required for its consideration. However, should any fees be determined to be necessary in connection with this paper,

Applicants respectfully request that any such fees be charged to Deposit Account No. 12-0615.

Applicants respectfully submit that the above-identified application claims priority under 35 USC § 120 from now allowed U.S. Serial No. 08/260,190 and that the Information Disclosure Statements submitted in that parent application complied with the requirements of 37 CFR § 1.98(a)-(c). Thus in accordance with 37 CFR § 1.98(d), Applicants respectfully submit that they are not herewith providing copies of the references cited on PTO Form 1449.


Applicants respectfully point out that the "filing of an information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in Section 1.56(b)" [37 CFR Section 1.97(h)]; and that an information disclosure statement filed in accordance with 37 CFR Section 1.97 "shall not be construed as a representation that a search has been made." [37 CFR Section 1.97(g)]

Further the identification of any document herein is not intended to be, and, Applicants respectfully submit, should not be construed as being, an admission that such a document, in fact, constitutes "prior art" within the meaning of the applicable laws, since, for example, a given document may have a later effective date than at first seems apparent, or the document may have an effective date which can be antedated. Applicants respectfully conclude on this point that the "prior

art" status of any document is a matter to be resolved during prosecution.

Thus, Applicants respectfully conclude that the citation of references herein is not intended to be an admission that any of the references are considered to be material or to constitute prior art, or that any of the references, either alone or in combination with any other references, would be sufficient to render any of the claims of the above-identified patent application unpatentable.

Respectfully submitted

A handwritten signature in cursive script, appearing to read "Leona L. Lauder".

Leona L. Lauder  
Attorney for Applicant  
Registration No. 30,863

Dated: 3-30-04

**INFORMATION DISCLOSURE CITATION**

APR 02 2004

(Use several sheets if necessary)

Docket Number (Optional)

D-0021.2-2

Application Number

10/795,933

Applicant(s)

Jan Zavada et al.

Filing Date

March 8, 2004

Group Art Unit

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
		WO 88/08854	11/17/88	WO				
		WO 93/18152	09/16/93	WO				

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

		DIVGI et al., "Scintigraphy of Renal Cell Carcinoma with I-131 Labelled Monoclonal Antibody (MAB) G250," <u>European Journal of Nuclear Medicine</u> , 19(8): 578 (Abstract 121-3) (August 23, 1992)
		FROHMAN et al., "Rapid production of full-length cDNAs from rare transcripts: Amplification using a single gene-specific oligonucleotide primer," <u>PNAS</u> (USA), 85: 8998-9002 (December 1988)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>		Docket Number (Optional) <b>D-0021.2-2</b>	Application Number <b>10/795,933</b>
*EXAMINER INITIAL		Applicant(s) <b>Jan Zavada et al.</b>	
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>		Filing Date <b>March 8, 2004</b>	Group Art Unit

*EXAMINER INITIAL	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>
	FROSCH et al., "Cloning and Characterisation of an Immunodominant Major Surface Antigen of Echinococcus multilocularis", <u>Molecular and Biochemical Parasitology</u> , 48: 121-130 (1991)
	KURTH et al., "Characterization of Human Renal Cell Carcinoma Tumor Lines by Means of Monoclonal Antibodies," <u>Prostate</u> , 6(4): 451 (Abstract) (1985)
	OOSTERWIJK et al., "The Expression of Renal Antigens in Renal Cell Carcinoma," <u>World Journal of Urology</u> , 2(2): 156-158 (1984)
	OOSTERWIJK et al., "Monoclonal Antibodies that Discriminate Between Renal Cell Carcinomas (RCC) and Other Malignancies," <u>Prostate</u> , 6(4): 451-452 (1985)
	OOSTERWIJK et al., "Immunohistochemical Analysis of Monoclonal Antibodies to Renal Antigens -- Application in the Diagnosis of Renal Cell Carcinoma," <u>American Journal of Pathology</u> , 123(2): 301-309 (May 1986)
	OOSTERWIJK et al., "Monoclonal Antibody G250 Recognizes a Determinant Present in Renal-Cell Carcinoma and Absent from Normal Kidney," <u>Int. J. Cancer</u> , 38: 489-494 (1986)
	OOSTERWIJK et al., "Relationship Between DNA Ploidy, Antigen Expression and Survival in Renal Cell Carcinoma," <u>Int. J. Cancer</u> , 42: 703-708 (1988)
	OOSTERWIJK et al., "Expression of Intermediate-sized Filaments in Developing and Adult Human Kidney and Renal Cell Carcinoma," <u>The Journal of Histochemistry and Cytochemistry</u> , 38(3): 385-392 (1990)
	OOSTERWIJK et al., "Antibody Localization in Human Renal Cell Carcinoma: A Phase I Study of Monoclonal Antibody G250," <u>Journal of Clinical Oncology</u> , 11(4): 738-750 (April 1993)
	OOSTERWIJK et al., "Molecular characterization of the Renal Cell Carcinoma-Associated Antigen G250," <u>Proceedings of the American Association for Cancer Research</u> , 37: 461 (March 1996)
	PASTOREKOVA et al., "A Novel Quasi-viral Agent, MaTU, Is a Two-Component System," <u>Virology</u> , 187: 620-626 (1992)
	STANBRIDGE et al., "Specific Chromosome Loss Associated with the Expression of Tumorigenicity in Human Cell Hybrids," <u>Somatic Cell Genetics</u> , 7(6): 699-712 (1981)
EXAMINER	DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>		Docket Number (Optional) <b>D-0021.2-2</b>	Application Number <b>10/795,933</b>
		Applicant(s) <b>Jan Zavada et al.</b>	
		Filing Date <b>March 8, 2004</b>	Group Art Unit

*EXAMINER INITIAL	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>
	STANBRIDGE et al., "Human Cell Hybrids: Analysis of Transformation and Tumorigenicity", <u>Science</u> , <b>215</b> : 252-259 (January 15, 1982)
	TWEEDIE and EDWARDS, "Mouse Carbonic Anhydrase III: Nucleotide Sequence and Expression Studies", <u>Biochemical Genetics</u> , <b>27</b> (1/2): 17-30 (1989)
	UEMURA et al., "Internal Image Anti-Idiotypic Antibodies Related to Renal-Cell Carcinoma-Associated Antigen G250," <u>Int. J. Cancer</u> , <b>56</b> : 609-614 (1994)
	UEMURA et al., "Expression of Tumor-Associated Antigen MN/G250 in Urologic Carcinoma: Potential Therapeutic Target," <u>Journal Urology</u> , <b>157</b> (4 Supp.): 377 (April 16, 1997)
	VAN DIJK et al., "Therapeutic Effects of Monoclonal Antibody G250, Interferons and Tumor Necrosis Factor, In Mice with Renal-Cell Carcinoma Xenografts," <u>Int. J. Cancer</u> , <b>56</b> : 262-268 (1994)
	YOUNG and DAVIS, "Efficient Isolation of Genes by Using Antibody Probes", <u>PNAS</u> (USA) <b>80</b> : 1194-1198 (March 1983)
	ZAVADA, "The Pseudotypic Paradox", <u>J. gen. Virol.</u> , <b>63</b> : 15-24 (1982)
	ZAVADA and ZAVADOVA, "A Transmissible Antigen Detected in Two Cell Lines Derived from Human Tumours", <u>J. gen. Virol.</u> , <b>24</b> : 327-337 (1974)
	Zavada and Zavadova, "An unusual transmissible agent -- MaTu", <u>Arch. Virol.</u> , <b>118</b> : 189-197 (1991)
	ZAVADA et al., "VSV Pseudotype Produced in Cell Line derived from Human Mammary Carcinoma", <u>Nature New Biology</u> , <b>240</b> : 124-125 (November 22, 1972)
	ZAVADA et al., "Tumorigenicity-Related Expression of MaTu Proteins in HeLa x Fibroblast Hybrids", Abstract presented at the XIX Meeting of the European Tumor Virus Group (May 1-4, 1991)
	ZAVADA et al., "Expression of MaTu-MN Protein in Human Tumor Cultures and in Clinical Specimens", <u>Int. J. Cancer</u> , <b>54</b> : 268-274 (1993)

EXAMINER	DATE CONSIDERED
----------	-----------------

**\*EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.